The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bellone, M.
Right arrow Articles by Rugarli, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellone, M.
Right arrow Articles by Rugarli, C.

The Journal of Immunology, Vol 158, Issue 2 783-789, Copyright © 1997 by American Association of Immunologists

ARTICLES

Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells

M Bellone, G Iezzi, A Martin-Fontecha, L Rivolta, AA Manfredi, MP Protti, M Freschi, P Dellabona, G Casorati and C Rugarli
Laboratory of Tumor Immunology, San Raffaele Scientific Institute, School of Medicine, University of Milan, Italy. bellonem@hsr.it

Naturally processed peptides, obtained by acid extraction of tumor cells, contain Ags able to activate specific CTL in vitro. We recently reported that the nonprofessional APC, RMA-S, expressing the B7.1 molecule (RMA-S/B7), pulsed with naturally processed peptides from the nonimmunogenic B16F1 melanoma (B16F1a.e.) primed syngenic CD8+ T cells against the tumor in vitro. Here, we show the rejection of B16F1 melanoma by C57BL/6 mice after immunization with RMA-S/B7 cells pulsed with B16F1a.e. This response is critically dependent on both CD4+ and CD8+ cells, but not on NK cells. However, only CD8+ T cells exert anti- B16F1 cytolitic activity in vitro. Moreover, RMA-S/B7 cells pulsed with B16F1a.e. can be used to prevent the growth of 24-h preestablished melanomas. These results may have important implications for the clinical use of natural peptide fractions of tumor cells as therapeutic cancer vaccines.


This article has been cited by other articles:


Home page
 J. Virol.Home page
K. A. Schoenly and D. B. Weiner
Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform "Spotty Business"
J. Virol., April 1, 2008; 82(7): 3166 - 3180.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Degl'Innocenti, M. Grioni, G. Capuano, E. Jachetti, M. Freschi, M. T.S. Bertilaccio, R. Hess-Michelini, C. Doglioni, and M. Bellone
Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells
Cancer Res., January 1, 2008; 68(1): 292 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
M. W. Graner and D. D. Bigner
Chaperone proteins and brain tumors: Potential targets and possible therapeutics
Neuro-oncol, July 1, 2005; 7(3): 260 - 278.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
S. V. Vaidya, S. E. Stepp, M. E. McNerney, J.-K. Lee, M. Bennett, K.-M. Lee, C. L. Stewart, V. Kumar, and P. A. Mathew
Targeted Disruption of the 2B4 Gene in Mice Reveals an In Vivo Role of 2B4 (CD244) in the Rejection of B16 Melanoma Cells
J. Immunol., January 15, 2005; 174(2): 800 - 807.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Camporeale, A. Boni, G. Iezzi, E. Degl'Innocenti, M. Grioni, A. Mondino, and M. Bellone
Critical Impact of the Kinetics of Dendritic Cells Activation on the in Vivo Induction of Tumor-specific T Lymphocytes
Cancer Res., July 1, 2003; 63(13): 3688 - 3694.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Shaif-Muthana, C. McIntyre, K. Sisley, I. Rennie, and A. Murray
Dead or Alive: Immunogenicity of Human Melanoma Cells When Presented by Dendritic Cells
Cancer Res., November 1, 2000; 60(22): 6441 - 6447.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
M. Bellone, D. Cantarella, P. Castiglioni, M. C. Crosti, A. Ronchetti, M. Moro, M. P. Garancini, G. Casorati, and P. Dellabona
Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma
J. Immunol., September 1, 2000; 165(5): 2651 - 2656.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. A. Ruefli, M. J. Smyth, and R. W. Johnstone
HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance
Blood, April 1, 2000; 95(7): 2378 - 2385.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Ronchetti, P. Rovere, G. Iezzi, G. Galati, S. Heltai, M. P. Protti, M. P. Garancini, A. A. Manfredi, C. Rugarli, and M. Bellone
Immunogenicity of Apoptotic Cells In Vivo: Role of Antigen Load, Antigen-Presenting Cells, and Cytokines
J. Immunol., July 1, 1999; 163(1): 130 - 136.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Maitre, J. M. Brown, M. Demcheva, J. R. Kelley, M. A. Lockett, J. Vournakis, and D. J. Cole
Primary T-Cell and Activated Macrophage Response Associated with Tumor Protection Using Peptide/Poly-N-Acetyl Glucosamine Vaccination
Clin. Cancer Res., May 1, 1999; 5(5): 1173 - 1182.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Men, I. Miconnet, D. Valmori, D. Rimoldi, J.-C. Cerottini, and P. Romero
Assessment of Immunogenicity of Human Melan-A Peptide Analogues in HLA-A*0201/Kb Transgenic Mice
J. Immunol., March 15, 1999; 162(6): 3566 - 3573.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
S. Manici, T. Sturniolo, M. A. Imro, J. Hammer, F. Sinigaglia, C. Noppen, G. Spagnoli, B. Mazzi, M. Bellone, P. Dellabona, et al.
Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11
J. Exp. Med., March 1, 1999; 189(5): 871 - 876.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Ostankovitch, A. Buzyn, D. Bonhomme, F. Connan, D. Bouscary, F. Heshmati, F. Dreyfus, J. Choppin, and J.-G. Guillet
Antileukemic HLA-Restricted T-Cell Clones Generated With Naturally Processed Peptides Eluted From Acute Myeloblastic Leukemia Blasts
Blood, July 1, 1998; 92(1): 19 - 24.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.